Celgene (NASDAQ:CELG) has been assigned a $166.00 target price by Oppenheimer in a research note issued to investors on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price objective would suggest a potential upside of 57.38% from the stock’s previous close.

A number of other brokerages also recently weighed in on CELG. Royal Bank of Canada reissued a “buy” rating and issued a $173.00 price target on shares of Celgene in a report on Thursday, October 5th. Morgan Stanley downgraded shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a report on Thursday, October 5th. Robert W. Baird reissued a “buy” rating and issued a $162.00 price target on shares of Celgene in a report on Thursday, September 21st. Cantor Fitzgerald reissued a “buy” rating and issued a $162.00 price target on shares of Celgene in a report on Tuesday, September 26th. Finally, Jefferies Group reissued a “buy” rating and issued a $160.00 price target on shares of Celgene in a report on Friday, September 15th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and nineteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $131.18.

Shares of Celgene (NASDAQ:CELG) traded down $0.01 during midday trading on Monday, reaching $105.48. 2,030,000 shares of the company’s stock were exchanged, compared to its average volume of 6,130,000. Celgene has a 52 week low of $94.55 and a 52 week high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The firm has a market cap of $83,050.00, a P/E ratio of 24.88, a price-to-earnings-growth ratio of 0.68 and a beta of 1.77.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the prior year, the company earned $1.58 EPS. Celgene’s revenue was up 10.2% on a year-over-year basis. sell-side analysts anticipate that Celgene will post 6.68 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in CELG. Janus Henderson Group PLC increased its holdings in Celgene by 4,290.5% in the second quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after buying an additional 8,217,433 shares during the last quarter. BlackRock Inc. increased its holdings in Celgene by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after buying an additional 3,084,227 shares during the last quarter. Oaktop Capital Management II L.P. acquired a new position in Celgene in the second quarter worth approximately $271,605,000. Arrowstreet Capital Limited Partnership increased its holdings in Celgene by 1,489.2% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock worth $247,669,000 after buying an additional 1,787,052 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Celgene by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after buying an additional 1,610,056 shares during the last quarter. Hedge funds and other institutional investors own 79.74% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Oppenheimer Analysts Give Celgene (CELG) a $166.00 Price Target” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.watchlistnews.com/oppenheimer-analysts-give-celgene-celg-a-166-00-price-target-3/1801351.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.